{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:27:23Z","timestamp":1793212043127,"version":"4.5.0"},"reference-count":100,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with inflammatory bowel disease (IBD) may be at increased risk of adverse neonatal outcomes. The aim of this study was to determine pooled incidences and risk factors for these outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medline, Embase, and Cochrane Library were searched through May 2019 for studies reporting adverse neonatal outcomes in IBD. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The pooled incidence of preterm birth, low birth weight, congenital anomalies, and infants transferred to the neonatal intensive care unit was 8.6% (95% CI, 7.0%\u201310.1%), 8.9% (95% CI, 7.3%\u201310.5%), 2.1% (95% CI, 1.6%\u20132.6%), and 4.9% (95% CI, 2.9%\u20136.9), respectively. Compared with healthy controls, patients with IBD were more likely to deliver infants with low birth weight (&amp;lt;2500 grams; OR, 2.78; 95% CI, 1.16\u20136.66) and infants admitted to the intensive care unit (OR, 3.33; 95% CI, 1.83\u20136.05). Patients with Crohn\u2019s disease had an increased incidence of congenital anomalies (OR, 3.03; 95% CI, 1.43\u20136.42). Among IBD patients, active disease was associated with increased incidence of preterm birth (OR, 2.06; 95% CI, 1.21\u20133.51), low birth weight (OR, 2.96; 95% CI, 1.54\u20135.70), and small for gestational age (OR, 2.62; 95% CI, 1.18\u20135.83). Antitumor necrosis factor (anti-TNF) use during pregnancy was associated with an increased incidence of neonatal intensive care unit admission (OR, 2.42; 95% CI, 1.31\u20134.45) and low birth weight (OR, 1.54; 95% CI, 1.01\u20132.35).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with IBD, particularly with active disease or requiring anti-TNF therapy, may be at increased risk of developing adverse neonatal outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaa122","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T05:10:03Z","timestamp":1590729003000},"page":"550-562","source":"Crossref","is-referenced-by-count":51,"title":["The Risk of Adverse Neonatal Outcomes With Maternal Inflammatory Bowel Disease: A Systematic Review and Meta-analysis"],"prefix":"10.1093","volume":"27","author":[{"given":"Kristel K","family":"Leung","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, University of Toronto , Toronto, Ontario, Canada"},{"name":"Department of Medicine, University of Toronto , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3192-0910","authenticated-orcid":false,"given":"Parul","family":"Tandon","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Toronto , Toronto, Ontario, Canada"},{"name":"Department of Medicine, University of Toronto , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Govardhanam","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Toronto , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Maxwell","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine, University of Toronto , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Toronto , Toronto, Ontario, Canada"},{"name":"Department of Medicine, University of Toronto , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"key":"2022092603083724000_CIT0001","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2018","journal-title":"Lancet."},{"key":"2022092603083724000_CIT0002","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/ecco-jcc\/jjw052","article-title":"Perceptions and attitudes towards medication adherence during pregnancy in inflammatory bowel disease","volume":"10","author":"Gallinger","year":"2016","journal-title":"J Crohns Colitis."},{"key":"2022092603083724000_CIT0003","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1155\/2015\/715354","article-title":"Does the level of reproductive knowledge specific to inflammatory bowel disease predict childlessness among women with inflammatory bowel disease?","volume":"29","author":"Huang","year":"2015","journal-title":"Can J Gastroenterol Hepatol."},{"key":"2022092603083724000_CIT0004","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gut.2006.108324","article-title":"A meta-analysis on the influence of inflammatory bowel disease on pregnancy","volume":"56","author":"Cornish","year":"2007","journal-title":"Gut."},{"key":"2022092603083724000_CIT0005","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1007\/s10620-015-3677-x","article-title":"Inflammatory bowel disease increases risk of adverse pregnancy outcomes: a meta-analysis","volume":"60","author":"O\u2019Toole","year":"2015","journal-title":"Dig Dis Sci."},{"key":"2022092603083724000_CIT0006","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"2022092603083724000_CIT0007","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials."},{"key":"2022092603083724000_CIT0008"},{"key":"2022092603083724000_CIT0009","author":"Wells"},{"key":"2022092603083724000_CIT0010","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00004836-200304000-00005","article-title":"Complications of pregnancy and child development after cessation of treatment with 6-mercaptopurine for inflammatory bowel disease","volume":"36","author":"Zlatanic","year":"2003","journal-title":"J Clin Gastroenterol."},{"key":"2022092603083724000_CIT0011","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0016-5085(90)91027-4","article-title":"Safety of azathioprine in pregnancy in inflammatory bowel disease","volume":"99","author":"Alstead","year":"1990","journal-title":"Gastroenterology."},{"key":"2022092603083724000_CIT0012","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ibd.20640","article-title":"Budesonide induction and maintenance therapy for Crohn\u2019s disease during pregnancy","volume":"15","author":"Beaulieu","year":"2009","journal-title":"Inflamm Bowel Dis."},{"key":"2022092603083724000_CIT0013","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3109\/00365521.2013.812141","article-title":"Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-\u03b1 therapy during pregnancy: three-center study","volume":"48","author":"Bortlik","year":"2013","journal-title":"Scand J Gastroenterol."},{"key":"2022092603083724000_CIT0014","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1365-2036.2011.04794.x","article-title":"Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006","volume":"34","author":"Bortoli","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"key":"2022092603083724000_CIT0015","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1440-1746.2006.04754.x","article-title":"Pregnancy before and after the diagnosis of inflammatory bowel diseases: retrospective case-control study","volume":"22","author":"Bortoli","year":"2007","journal-title":"J Gastroenterol Hepatol."},{"key":"2022092603083724000_CIT0016","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.crohns.2012.08.012","article-title":"Maternal inflammatory bowel disease has short and long-term effects on the health of their offspring: a multicenter study in Israel","volume":"7","author":"Dotan","year":"2013","journal-title":"J Crohns Colitis."},{"key":"2022092603083724000_CIT0017","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/ecco-jcc\/jjv006","article-title":"Intrapartum corticosteroid use significantly increases the risk of gestational diabetes in women with inflammatory bowel disease","volume":"9","author":"Leung","year":"2015","journal-title":"J Crohns Colitis."},{"key":"2022092603083724000_CIT0018","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/s41395-018-0202-9","article-title":"Pregnancy outcomes reported during the 13-year TREAT registry: a descriptive report","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"2022092603083724000_CIT0019","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/j.1572-0241.2000.01852.x","article-title":"Crohn\u2019s disease, pregnancy, and birth weight","volume":"95","author":"Moser","year":"2000","journal-title":"Am J Gastroenterol."},{"key":"2022092603083724000_CIT0020","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.3109\/14767058.2012.684176","article-title":"Inflammatory bowel disease: risk factors for adverse pregnancy outcome and the impact of maternal weight gain","volume":"25","author":"Oron","year":"2012","journal-title":"J Matern Fetal Neonatal Med."},{"key":"2022092603083724000_CIT0021","first-page":"121","article-title":"Pregnancy outcomes in inflammatory bowel disease: experiences from a Western Australian Tertiary Center","volume":"32","author":"Picardo","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"2022092603083724000_CIT0022","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s10350-004-6411-x","article-title":"Pregnancy, delivery, and pouch function after ileal pouch-anal anastomosis for ulcerative colitis","volume":"45","author":"Ravid","year":"2002","journal-title":"Dis Colon Rectum."},{"key":"2022092603083724000_CIT0023","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1055\/s-2007-994469","article-title":"Course of Crohn\u2019s disease during pregnancy and its effect on pregnancy outcome: a retrospective review","volume":"12","author":"Rogers","year":"1995","journal-title":"Am J Perinatol."},{"key":"2022092603083724000_CIT0024","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/apt.12833","article-title":"Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease","volume":"40","author":"Seirafi","year":"2014","journal-title":"Aliment Pharmacol Ther."},{"key":"2022092603083724000_CIT0025","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/S1873-9946(13)60297-4","article-title":"P276 Clinical outcomes of children with prenatal exposure to anti-TNF therapy for maternal inflammatory bowel disease","volume":"7","author":"Yassin","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2022092603083724000_CIT0026","doi-asserted-by":"crossref","first-page":"S515","DOI":"10.14309\/00000434-201410002-01741","article-title":"Outcome of immunosuppressive treatment in pregnant IBD patients","volume":"109","author":"Arsenescu","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2022092603083724000_CIT0027","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/ibd.21120","article-title":"Relationships between inflammatory bowel disease and perinatal factors: both maternal and paternal disease are related to preterm birth of offspring","volume":"16","author":"Bengtson","year":"2010","journal-title":"Inflamm Bowel Dis."},{"key":"2022092603083724000_CIT0028","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1016\/S1873-9946(14)60299-3","article-title":"P178 Outcomes of pregnancies among women with inflammatory bowel disease: results from a single-center cohort","volume":"8","author":"Camba","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2022092603083724000_CIT0029","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/ajg.2012.430","article-title":"Safety of thiopurines and anti-TNF-\u03b1 drugs during pregnancy in patients with inflammatory bowel disease","volume":"108","author":"Casanova","year":"2013","journal-title":"Am J Gastroenterol."},{"key":"2022092603083724000_CIT0030","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ajg.2017.501","article-title":"Long-term safety of in utero exposure to anti-TNF\u03b1 drugs for the treatment of inflammatory bowel disease: results from the Multicenter European TEDDY Study","volume":"113","author":"Chaparro","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"2022092603083724000_CIT0031","doi-asserted-by":"crossref","first-page":"S297","DOI":"10.1093\/ecco-jcc\/jjx002.559","article-title":"P434 Joint Inflammatory Bowel Disease\u2013Obstetric clinics: outcomes in 95 pregnancies at a tertiary centre over a 3-year period","volume":"11","author":"Chew","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2022092603083724000_CIT0032","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3899\/jrheum.140189","article-title":"Pregnancy outcomes in subjects exposed to certolizumab pegol","volume":"42","author":"Clowse","year":"2015","journal-title":"J Rheumatol."},{"key":"2022092603083724000_CIT0033","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/ajg.2016.254","article-title":"The effects of active IBD during pregnancy in the era of novel IBD therapies","volume":"111","author":"de Lima-Karagiannis","year":"2016","journal-title":"Am J Gastroenterol."},{"key":"2022092603083724000_CIT0034","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/ibd\/izy294","article-title":"Safety of anti-TNF-alpha therapy during pregnancy on long-term outcome of exposed children: a controlled, multicenter observation","volume":"25","author":"Duricova","year":"2019","journal-title":"Inflamm Bowel Dis."},{"key":"2022092603083724000_CIT0035","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ijgo.2005.06.003","article-title":"Inflammatory bowel disease and preterm delivery","volume":"90","author":"Elbaz","year":"2005","journal-title":"Int J Gynaecol Obstet."},{"key":"2022092603083724000_CIT0036","doi-asserted-by":"crossref","first-page":"S243","DOI":"10.1016\/S1873-9946(13)60601-7","article-title":"P580 biologic therapy in pregnancy and inflammatory bowel disease: a prospective 7 year study: clinical outcome","volume":"7","author":"Habal","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2022092603083724000_CIT0037","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s10350-004-0569-0","article-title":"Pregnancy and delivery before and after ileal pouch-anal anastomosis for inflammatory bowel disease: immediate and long-term consequences and outcomes","volume":"47","author":"Hahnloser","year":"2004","journal-title":"Dis Colon Rectum."},{"key":"2022092603083724000_CIT0038","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2169\/internalmedicine.8550-16","article-title":"Relationship between the clinical course of ulcerative colitis during pregnancy and the outcomes of pregnancy: a retrospective evaluation","volume":"57","author":"Ito","year":"2018","journal-title":"Intern Med."},{"key":"2022092603083724000_CIT0039","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/gutjnl-2012-303615","article-title":"Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease","volume":"63","author":"Jharap","year":"2014","journal-title":"Gut."},{"key":"2022092603083724000_CIT0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/ibd\/izz110","article-title":"Anti-TNF therapy in pregnant women with inflammatory bowel disease: effects of therapeutic strategies on disease behavior and birth outcomes","volume":"26","author":"Julsgaard","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2022092603083724000_CIT0041","doi-asserted-by":"crossref","first-page":"S246","DOI":"10.1093\/ecco-jcc\/jjx180.415","article-title":"P288 Pregnancy and delivery outcomes in patients with ulcerative colitis","volume":"12","author":"Kashiwagi","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"1","key":"2022092603083724000_CIT0042","doi-asserted-by":"crossref","first-page":"20","DOI":"10.14735\/amgh201820","article-title":"Pregnancy outcomes in women with inflammatory bowel disease treated with biosimilar infliximab","volume":"72","author":"Kol\u00e1\u0159","year":"2018","journal-title":"Gastroenterol a hepatol"},{"key":"2022092603083724000_CIT0043","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/ibd\/izy081","article-title":"Pregnancy-onset inflammatory bowel disease: a subtle diagnosis","volume":"24","author":"Koslowsky","year":"2018","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2022092603083724000_CIT0044","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1016\/S1590-8658(18)30564-4","article-title":"P.07.14 management of inflammatory bowel disease during pregnancy: a single center experience","volume":"50","author":"Laino","year":"2018","journal-title":"Dig Liver Dis"},{"key":"2022092603083724000_CIT0045","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2005.02405.x","article-title":"Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn\u2019s disease","volume":"21","author":"Mahadevan","year":"2005","journal-title":"Aliment Pharmacol Ther."},{"key":"2022092603083724000_CIT0046","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/apt.13960","article-title":"Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease","volume":"45","author":"Mahadevan","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"key":"2022092603083724000_CIT0047","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/ecco-jcc\/jjy142","article-title":"Outcome of pregnancies in female patients with inflammatory bowel diseases treated with vedolizumab","volume":"13","author":"Moens","year":"2019","journal-title":"J Crohns Colitis."},{"key":"2022092603083724000_CIT0048","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1097\/01.MIB.0000456829.38396.9b","article-title":"P-090African-American women with inflammatory bowel disease deliver more low birth weight infants than white women","volume":"20","author":"Monica","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2022092603083724000_CIT0049","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1572-0241.2004.04140.x","article-title":"The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients","volume":"99","author":"Moskovitz","year":"2004","journal-title":"Am J Gastroenterol."},{"key":"2022092603083724000_CIT0050","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.crohns.2011.02.003","article-title":"Conception and pregnancy outcome in women with inflammatory bowel disease: a multicentre study from Japan","volume":"5","author":"Naganuma","year":"2011","journal-title":"J Crohns Colitis."},{"key":"2022092603083724000_CIT0051","first-page":"P336","article-title":"P336. TNF alpha inhibitor use in pregnancy: experience in a European cohort","author":"Kelly","year":"2014","journal-title":"ECCO Congress Abstracts."},{"key":"2022092603083724000_CIT0052","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1007\/s10620-016-4353-5","article-title":"Long-term disease course and pregnancy outcomes in women with inflammatory bowel disease: an Indian Cohort Study","volume":"62","author":"Padhan","year":"2017","journal-title":"Dig Dis Sci."},{"key":"2022092603083724000_CIT0053","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s12664-015-0542-y","article-title":"Extent of disease is a major outcome predictor in patients with ulcerative colitis and pregnancy","volume":"34","author":"Puri","year":"2015","journal-title":"Indian J Gastroenterol."},{"key":"2022092603083724000_CIT0054","doi-asserted-by":"crossref","first-page":"S250","DOI":"10.1016\/S1873-9946(14)60563-8","article-title":"P443 Infliximab use during pregnancy in Crohn\u2019s disease","volume":"8","author":"Ramos","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2022092603083724000_CIT0055","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/j.1572-0241.2006.00602.x","article-title":"Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease","volume":"101","author":"Riis","year":"2006","journal-title":"Am J Gastroenterol."},{"key":"2022092603083724000_CIT0056","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/ibd.21583","article-title":"Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy","volume":"17","author":"Schnitzler","year":"2011","journal-title":"Inflamm Bowel Dis."},{"key":"2022092603083724000_CIT0057","first-page":"A99","article-title":"PWE-064 Combined inflammatory bowel disease\u2013 obstetric clinic, a district general hospital experience over 2 years","volume":"67","author":"Thoua","year":"2018","journal-title":"Gut"},{"key":"2022092603083724000_CIT0058","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/j.clnme.2014.07.001","article-title":"Is dietary treatment of Crohn\u2019s disease safe in pregnancy? A retrospective study","volume":"9","author":"Woolner","year":"2014","journal-title":"e-SPEN Journal"},{"key":"2022092603083724000_CIT0059","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1093\/ecco-jcc\/jjx002.276","article-title":"P150 Pregnancy complications and outcomes in patients with inflammatory bowel disease","volume":"11","author":"Yokoyama","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"6","key":"2022092603083724000_CIT0060","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(18)32245-5","article-title":"Su1899 - vedolizumab is safe for use in pregnant patients with IBD; report of our preliminary data","volume":"154","author":"Shitrit","year":"2018","journal-title":"Gastroenterology"},{"key":"2022092603083724000_CIT0061","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5217\/ir.2018.00071","article-title":"Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children\u2019s immunity","volume":"17","author":"Lee","year":"2019","journal-title":"Intest Res."},{"key":"2022092603083724000_CIT0062","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0016-5085(98)70628-6","article-title":"The safety of mesalamine in human pregnancy: a prospective controlled cohort study","volume":"114","author":"Diav-Citrin","year":"1998","journal-title":"Gastroenterology."},{"key":"2022092603083724000_CIT0063","first-page":"211","article-title":"The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome","volume":"6","author":"Baiocco","year":"1984","journal-title":"J Clin Gastroenterol."},{"key":"2022092603083724000_CIT0064","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4321\/S1130-01082012000200003","article-title":"Is safety infliximb during pregnancy in patients with inflammatory bowel disease?","volume":"104","author":"Arg\u00fcelles-Arias","year":"2012","journal-title":"Rev Esp Enferm Dig."},{"key":"2022092603083724000_CIT0065","doi-asserted-by":"crossref","first-page":"S252","DOI":"10.1016\/S1873-9946(13)60626-1","article-title":"P605 Adalimumab (ADA) and infliximab (IFX) therapy during pregnancy in IBD: a prospective assessment of outcome, safety and cord blood levels","volume":"7","author":"Traussnigg","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2022092603083724000_CIT0066","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/1756-0500-6-210","article-title":"Importance of appropriate pharmaceutical management in pregnant women with ulcerative colitis","volume":"6","author":"Ujihara","year":"2013","journal-title":"BMC Res Notes."},{"key":"2022092603083724000_CIT0067","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/BF02051924","article-title":"Crohn\u2019s disease and pregnancy","volume":"33","author":"Woolfson","year":"1990","journal-title":"Dis Colon Rectum."},{"key":"2022092603083724000_CIT0068","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/jp.2017.109","article-title":"Autoimmune conditions and comorbid depression in pregnancy: examining the risk of preterm birth and preeclampsia","volume":"37","author":"Bandoli","year":"2017","journal-title":"J Perinatol."},{"issue":"5","key":"2022092603083724000_CIT0069","first-page":"A","article-title":"1874 - pregnancy outcomes in women exposed to adalimumab: an update on the autoimmune diseases in pregnancy project","volume":"136","author":"Johnson","year":"2011","journal-title":"Arth Rheum."},{"key":"2022092603083724000_CIT0070","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41395-018-0176-7","article-title":"Continuous anti-TNF\u03b1 use throughout pregnancy: possible complications for the mother but not for the fetus. a retrospective cohort on the French National Health Insurance Database (EVASION)","volume":"113","author":"Luu","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"2022092603083724000_CIT0071","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1097\/MIB.0000000000000802","article-title":"Adverse pregnancy outcomes among women with inflammatory bowel disease: a population-based study from England","volume":"22","author":"Abdul Sultan","year":"2016","journal-title":"Inflamm Bowel Dis."},{"key":"2022092603083724000_CIT0072","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1053\/j.gastro.2013.09.061","article-title":"Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications","volume":"146","author":"Ban","year":"2014","journal-title":"Gastroenterology."},{"key":"2022092603083724000_CIT0073","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/14767050410001668662","article-title":"Perinatal outcomes in inflammatory bowel disease","volume":"15","author":"Bush","year":"2004","journal-title":"J Matern Fetal Neonatal Med."},{"key":"2022092603083724000_CIT0074","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1572-0241.2002.05543.x","article-title":"Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study","volume":"97","author":"Dominitz","year":"2002","journal-title":"Am J Gastroenterol."},{"issue":"1","key":"2022092603083724000_CIT0075","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.ajog.2012.10.336","article-title":"171: Ulcerative colitis in pregnancy","volume":"208","author":"Emerson","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"2022092603083724000_CIT0076","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/ecco-jcc\/jjw083","article-title":"Maternal inflammatory bowel disease during pregnancy is not a risk factor for long-term morbidity of the offspring","volume":"10","author":"Freud","year":"2016","journal-title":"J Crohns Colitis."},{"key":"2022092603083724000_CIT0077","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ajg.2009.562","article-title":"Ulcerative colitis and pregnancy outcomes in an Asian population","volume":"105","author":"Lin","year":"2010","journal-title":"Am J Gastroenterol."},{"key":"2022092603083724000_CIT0078","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1572-0241.2007.01216.x","article-title":"Therapeutic drug use in women with Crohn\u2019s disease and birth outcomes: a Danish nationwide cohort study","volume":"102","author":"N\u00f8rg\u00e5rd","year":"2007","journal-title":"Am J Gastroenterol."},{"key":"2022092603083724000_CIT0079","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2036.2010.04538.x","article-title":"The effects of pre- and post-pregnancy inflammatory bowel disease diagnosis on birth outcomes","volume":"33","author":"Raatikainen","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"key":"2022092603083724000_CIT0080","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1111\/1471-0528.13946","article-title":"Inflammatory bowel disease in pregnancy: a population-based study of prevalence and pregnancy outcomes","volume":"123","author":"Shand","year":"2016","journal-title":"Bjog."},{"key":"2022092603083724000_CIT0081","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.crohns.2011.01.009","article-title":"The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD)","volume":"5","author":"Shim","year":"2011","journal-title":"J Crohns Colitis."},{"key":"2022092603083724000_CIT0082","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/MIB.0000000000001102","article-title":"The effect of disease activity on birth outcomes in a nationwide cohort of women with moderate to severe inflammatory bowel disease","volume":"23","author":"Kammerlander","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"2022092603083724000_CIT0083","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s10620-017-4547-5","article-title":"Inadequate gestational weight gain predicts adverse pregnancy outcomes in mothers with inflammatory bowel disease: results from a prospective US pregnancy cohort","volume":"62","author":"Bengtson","year":"2017","journal-title":"Dig Dis Sci."},{"key":"2022092603083724000_CIT0084","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jri.2016.04.098","article-title":"Pregnancy outcomes in Japanese women with inflammatory bowel disease (IBD)","volume":"115","author":"Takeyama","year":"2016","journal-title":"J Reprod Immunol"},{"key":"2022092603083724000_CIT0085","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.cgh.2017.02.041","article-title":"Use of thiopurines during conception and pregnancy is not associated with adverse pregnancy outcomes or health of infants at one year in a prospective study","volume":"15","author":"Kanis","year":"2017","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022092603083724000_CIT0086","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/ibd\/izy160","article-title":"Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis","volume":"24","author":"Mahadevan","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2022092603083724000_CIT0087","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2018.12.022","article-title":"Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group","volume":"156","author":"Mahadevan","year":"2019","journal-title":"Gastroenterology."},{"key":"2022092603083724000_CIT0088","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1111\/j.1572-0241.2007.01355.x","article-title":"Disease activity in pregnant women with Crohn\u2019s disease and birth outcomes: a regional Danish cohort study","volume":"102","author":"N\u00f8rg\u00e5rd","year":"2007","journal-title":"Am J Gastroenterol."},{"key":"2022092603083724000_CIT0089","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/EDE.0000000000001055","article-title":"Timing and amount of gestational weight gain in association with adverse birth outcomes","volume":"30","author":"Darling","year":"2019","journal-title":"Epidemiology."},{"key":"2022092603083724000_CIT0090","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clnu.2015.03.001","article-title":"Diagnostic criteria for malnutrition - an ESPEN consensus statement","volume":"34","author":"Cederholm","year":"2015","journal-title":"Clin Nutr."},{"key":"2022092603083724000_CIT0091","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/ibd.20429","article-title":"Nationwide prevalence and prognostic significance of clinically diagnosable protein-calorie malnutrition in hospitalized inflammatory bowel disease patients","volume":"14","author":"Nguyen","year":"2008","journal-title":"Inflamm Bowel Dis."},{"key":"2022092603083724000_CIT0092","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejim.2010.04.012","article-title":"Nutritional status in patients with active inflammatory bowel disease: prevalence of malnutrition and methods for routine nutritional assessment","volume":"21","author":"Mijac","year":"2010","journal-title":"Eur J Intern Med."},{"key":"2022092603083724000_CIT0093","doi-asserted-by":"crossref","first-page":"e1090","DOI":"10.1016\/S2214-109X(17)30371-6","article-title":"Modifiers of the effect of maternal multiple micronutrient supplementation on stillbirth, birth outcomes, and infant mortality: a meta-analysis of individual patient data from 17 randomised trials in low-income and middle-income countries","volume":"5","author":"Smith","year":"2017","journal-title":"Lancet Glob Health."},{"key":"2022092603083724000_CIT0094","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/978-90-481-9485-8_20","article-title":"The prevalence of congenital anomalies in Europe","volume":"686","author":"Dolk","year":"2010","journal-title":"Adv Exp Med Biol."},{"key":"2022092603083724000_CIT0095","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/ecco-jcc\/jjv234","article-title":"Anti-tumour necrosis factor \u03b1 therapies and inflammatory bowel disease pregnancy outcomes: a meta-analysis","volume":"10","author":"Shihab","year":"2016","journal-title":"J Crohns Colitis."},{"key":"2022092603083724000_CIT0096","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/0960327114550882","article-title":"Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis","volume":"34","author":"Mozaffari","year":"2015","journal-title":"Hum Exp Toxicol."},{"key":"2022092603083724000_CIT0097","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.3748\/wjg.v19.i17.2591","article-title":"Tumor necrosis factor-\u03b1 inhibitor therapy and fetal risk: a systematic literature review","volume":"1","author":"Marchioni","year":"2013","journal-title":"World J Gastroenterol."},{"key":"2022092603083724000_CIT0098","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ibd.22948","article-title":"Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease","volume":"19","author":"Akbari","year":"2013","journal-title":"Inflamm Bowel Dis."},{"key":"2022092603083724000_CIT0099","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.14309\/ajg.0000000000000186","article-title":"Exposure to vedolizumab in IBD pregnant women appears of low risk for mother and neonate: a first prospective comparison study","volume":"114","author":"Bar-Gil Shitrit","year":"2019","journal-title":"Am J Gastroenterol."},{"key":"2022092603083724000_CIT0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MCG.0000000000001244","article-title":"Noninvasive methods for assessing inflammatory bowel disease activity in pregnancy: a systematic review","volume":"53","author":"Tandon","year":"2019","journal-title":"J Clin Gastroenterol."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/27\/4\/550\/46041192\/izaa122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/27\/4\/550\/46041192\/izaa122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T23:11:28Z","timestamp":1664147488000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/27\/4\/550\/5848466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":100,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,5,29]]},"published-print":{"date-parts":[[2021,3,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaa122","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2020,5,29]]}}}